We found about 52.6% (20/38) of ERBB2 mutations were from breast cancer patients and 44.7% (17/38) were from lung cancer patients, with 59% of all mutations in β3‐αC loop were druggable. This evidence concerns the gene ERBB2 and lung cancer.